Biopath Holdings, Inc
3293 Harrison Boulevard
Suite 230
Ogden,
UT 84403
United States - Map
Phone: 801-399-5500
Web Site: http://www.biopathholdings.com
| Bio-Path Holdings, Inc., through its subsidiary, Bio-Path, Inc., develops liposomal drug delivery systems. Its drug delivery platform technology enables systemic distribution of nucleic acid drugs, as well as antisense, small interfering RNA (siRNA), and small molecules for treatment of cancer. The companys two lead drug candidates treat acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, and follicular lymphoma; and a siRNA ovarian cancer drug undergoing final pre-clinical development. Bio-Path Holdings, Inc. was founded in 2007 and is based in Ogden, Utah. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Peter H. Nielsen , 59
Co-Founder, Chairman, Chief Exec. Officer, Pres, Chief Financial Officer, Chief Accounting Officer and Treasurer |
$
250.00K | N/A | Dr. Douglas P. Morris , 52
Co-Founder, VP of Corp. Devel., Sec., Director and Member of Compensation Committee |
$
120.00K | N/A | Mr. Dai-Shan Wong ,
Director of Regulatory Affairs & Quality Control |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.14% Nasdaq 
Profile
